A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Seve… (NCT06035393) | Clinical Trial Compass
TerminatedPhase 2
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Stopped: Sponsor's R\&D strategy adjusted.
China82 participantsStarted 2024-01-15
Plain-language summary
This is a randomized, double blind, double dummy, active-controlled, parallel-group study to assess the efficacy and Safety of HRG2005 inhalation in patients with moderate to severe chronic obstructive pulmonary disease. Approximately 200 patients with moderate to severe COPD will be randomized into the study.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Able and willing to provide written informed consent and to comply with the study protocol;
✓. Subjects 40 years of age or older (inclusive), Male or female subjects;
✓. Subjects with an established clinical history of COPD;
✓. A post-bronchodilator FEV1/FVC ratio must be \<0.7 at Screening and FEV1 must be \<80% and ≥30% predicted normal at pre-randomization;
✓. a documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbation in the previous 12 months;
✓. Tobacco Use: Current or former smokers with a history of at least 10 pack-years of cigarette smoking;
✓. A score of ≥10 on the COPD Assessment Test (CAT) at pre-randomization.
Exclusion criteria
✕. Subjects who required systemic corticosteroids or antibiotics or hospitalized due to poorly controlled COPD or who had lower respiratory tract infections that required antibiotics within 4 weeks prior to Screening to pre-randomization;
What they're measuring
1
Change from baseline in morning pre-dose trough FEV1 at week 12
. Subjects who had respiratory tract infections that required antibiotics within 2 weeks prior to Screening to pre-randomization;
✕. Subjects with other respiratory or respiratory related diseases, including but not limited to asthma, active tuberculosis, lung cancer, interstitial pulmonary disease, α1-antitrypsin deficiency, pulmonary heart disease, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary disease;
✕. Subjects with lung volume reduction surgery within the 12 months prior to Screening;
✕. Subjects who have Other known serious medical conditions；
✕. Subjects receiving oxygen therapy required for greater than 15 hours a day;